WHO Sounds Alert Over Critical Scarcity of Weight-Loss Jabs

Under 10% of individuals eligible to benefit from obesity jabs like Wegovy are able to get them, states the World Health Organization as it publishes its initial guidance on the medications.

Considering over a billion people worldwide now obese, it is calling for more widespread and fairer availability to these injectable treatments.

Based on estimates, more than two billion could be obese by 2030 without intervention.

"Our new guidelines acknowledges that obesity is a long-term condition that can be treated with thorough and ongoing support," said the agency's head Tedros Adhanom Ghebreyesus.

Substantial prices, insufficient output, and supply-chain constraints are key obstacles to broad availability to the treatments that can assist patients in reducing considerable body mass, explains the organization.

GLP-1 Therapy Scarcity

Even in the current best projected case, the supply of these medications would only suffice for about 100 million people – fewer than 10% of those who need them, per the health organization.

The advice urges nations and manufacturers to widen access, through strategies including licensing agreements.

A patent on the active ingredient – the core component of a leading brand – is due to expire in a number of nations in 2026.

How Obesity Drugs Operate

The injections imitate a natural hormone to delay gastric emptying, reduce hunger and boost satiety so individuals eat less.

People typically start to lose weight within a few weeks of beginning the once-weekly jabs.

Research indicates people may put most of the weight back on after a year of stopping the treatment, when their usual hunger resume.

Being carrying excess weight elevates your chance for developing health problems, such as diabetes, heart disease, stroke, and some cancers.

Obesity concerns individuals in all nations and was associated with millions of deaths worldwide in 2024, as per the health agency.